DISCRETE ASSAY FOR INTEGRATED HPV DNA IN CERVICAL CELLS
宫颈细胞中整合 HPV DNA 的离散检测
基本信息
- 批准号:6439149
- 负责人:
- 金额:$ 4.93万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2000
- 资助国家:美国
- 起止时间:2000-09-01 至 2001-03-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Current studies indicate that development of cervical cancer is strongly linked to the DNA integration of several subtypes of the human papillomavirus (HPV). The Pap test has helped in the early detection of precursor lesions; however, results are inconclusive when low grade lesions are detected. In these cases, a solution based hybridization method can be used to screen for the presence and viral burden of common HPV subtypes associated with cervical cancer. The presence of HPV, however, is not a useful indicator of subsequent development of cervical cancer. A test which can determine the occurrence of viral integration is a better indicator of disease. Current in situ hybridization methods have limited success in distinguishing integrated virus from episomal virus. Analysis is difficult because both episomal and integrated virus often coexist, and the "diffuse" pattern indicating episomal virus often masks the "dot" pattern indicating integrated virus. By combining single cell gel microdrop (GMD) encapsulation technology, in situ hybridization and nuclear fractionation techniques, this Phase I proposal aims to develop an assay which will unambiguously distinguish integrated virus from episomal virus. Use of GMD technology will also reduce cell loss, facilitating rare cell detection. PROPOSED COMMERCIAL APPLICATIONS: The assay will permit early detection of cervical cancer and highly specific assessment of viral pathogenic mechanisms directly linked to cervical cancer, facilitating early treatment and reducing mortality rates.
目前的研究表明,宫颈癌的发生与人乳头瘤病毒(HPV)几种亚型的DNA整合密切相关。巴氏试验有助于早期发现前驱病变;然而,当检测到低级别病变时,结果是不确定的。在这些情况下,基于溶液的杂交方法可用于筛查与宫颈癌相关的常见HPV亚型的存在和病毒负荷。然而,HPV的存在并不是宫颈癌后续发展的有用指标。可以确定病毒整合发生的测试是疾病的更好指标。 目前的原位杂交方法在区分整合型病毒和游离型病毒方面的成功率有限。 分析是困难的,因为附加型和整合型病毒经常共存,并且指示附加型病毒的“扩散”模式经常掩盖指示整合型病毒的“点”模式。 通过结合单细胞凝胶微滴(GMD)包封技术,原位杂交和核分馏技术,这个第一阶段的建议,旨在开发一种检测,将明确区分整合的病毒从游离型病毒。 使用GMD技术还将减少细胞损失,促进稀有细胞检测。拟议的商业应用:该检测方法将允许早期检测宫颈癌和高度特异性评估与宫颈癌直接相关的病毒致病机制,促进早期治疗和降低死亡率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PHILLIP T MOEN其他文献
PHILLIP T MOEN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PHILLIP T MOEN', 18)}}的其他基金
Detecting Integrated HPV DNA in Immunocompromised Women
检测免疫功能低下女性的整合 HPV DNA
- 批准号:
6909621 - 财政年份:2005
- 资助金额:
$ 4.93万 - 项目类别:
Rapid FISH Assay for Oncogenic Papillomavirus RNAs
致癌乳头瘤病毒 RNA 的快速 FISH 检测
- 批准号:
6783732 - 财政年份:2004
- 资助金额:
$ 4.93万 - 项目类别:
High Sensitivity Detection of Viral DNAs in Cancer Cells
高灵敏度检测癌细胞中的病毒 DNA
- 批准号:
6401917 - 财政年份:2001
- 资助金额:
$ 4.93万 - 项目类别:
DISCRETE ASSAY FOR INTEGRATED HPV DNA IN CERVICAL CELLS
宫颈细胞中整合 HPV DNA 的离散检测
- 批准号:
6203908 - 财政年份:2000
- 资助金额:
$ 4.93万 - 项目类别:
Discrete Assay for Integrated HPV DNA in Cervical Cells
宫颈细胞中整合 HPV DNA 的离散检测
- 批准号:
6481488 - 财政年份:2000
- 资助金额:
$ 4.93万 - 项目类别:
Discrete Assay for Integrated HPV DNA in Cervical Cells
宫颈细胞中整合 HPV DNA 的离散检测
- 批准号:
6658089 - 财政年份:2000
- 资助金额:
$ 4.93万 - 项目类别:
NOVEL METHOD FOR DETECTING NON-HODGKIN'S LYMPHOMA
检测非霍奇金淋巴瘤的新方法
- 批准号:
6130918 - 财政年份:2000
- 资助金额:
$ 4.93万 - 项目类别: